GlassScriptPhysician profile
Laurel B Owens
NPI 1104073907
$245,832.63
in general payments reported to CMS, 2019-2025
18 companies · $64K in 2025
The $64K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33K · 2022: $58K · 2023: $48K · 2024: $42K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112K · Travel and Lodging: $18K · Consulting Fee: $15K · Food and Beverage: $10K · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111,525.00 |
| Travel and Lodging | $18,243.36 |
| Consulting Fee | $14,775.00 |
| Food and Beverage | $10,327.44 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $154,222.44 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $83,516.46 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,631.38 | 2021-2025 | Caplyta |
| Allergan, INC. | $1,112.43 | 2021 | |
| Janssen Pharmaceuticals, INC | $859.31 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $794.21 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $664.42 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $643.88 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $528.55 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $519.01 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $462.08 | 2024-2025 | Cobenfy |
| Indivior INC. | $418.68 | 2021-2024 | Perseris, Sublocade |
| Noven Therapeutics, LLC | $210.72 | 2021-2025 | Secuado |
| Axsome Therapeutics, INC. | $152.01 | 2022-2025 | Auvelity |
| Janssen Biotech, INC. | $35.92 | 2025 | Tremfya |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $34.34 | 2021 | |
| Tonix Medicines, INC. | $13.46 | 2025 | Tonmya |
| Merck Sharp & Dohme LLC | $13.33 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurel Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.